The DOI matches its Crossref record.
Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: The evidence for concurrent chemoradiotherapy (CT-RT) in International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix is not robust. This study reports the final results of a randomized clinical trial of concurrent cisplatin-based CT-RT and radiotherapy alone (RT) in women with FIGO stage IIIB squamous cell carcinoma of the uterine cervix. OBJECTIVE: To investigate the benefit of concurrent CT-RT in FIGO stage IIIB squamous cell carcinoma of the uterine cervix. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 open-label randomized clinical trial accrued 850 women in Mumbai, India, between July 7, 2003, and September 22, 2011. Of 2121 screened, 850 women with FIGO stage IIIB squamous cell carcinoma of the uterine cervix suitable for concurrent cisplatin chemotherapy were randomly assigned to CT-RT and RT using block randomization (1:1). The data were updated for a minimum follow-up period of 5 years until December 2016. The final analyses were performed in February and March 2017. This single-institution study was conducted at a tertiary cancer center setting. INTERVENTIONS: Randomization to receive RT (RT arm), comprising a combination of external beam RT (50 Gy in 25 fractions over 5 weeks) and brachytherapy, or to receive in addition to the same RT concurrent weekly cisplatin chemotherapy (40 mg/m2 per week) (CT-RT arm). MAIN OUTCOMES AND MEASURES: The primary end point was 5-year disease-free survival (DFS), defined as the time between the date of randomization and the date of any recurrence or death (whichever occurred first) in the intent-to-treat population. RESULTS: This trial included 424 women assigned to CT-RT (mean [SD] age, 49.4 [7.9] years) and 426 women assigned to RT (mean [SD] age, 49.3 [7.9] years). At a median follow-up of 88 months (interquartile range, 61.3-113.1 months), there were 222 recurrences and 213 deaths in the CT-RT arm and 252 recurrences and 243 deaths in the RT arm. The 5-year DFS was significantly higher in the CT-RT arm (52.3%; 95% CI, 52.2%-52.4%) compared with the RT arm (43.8%; 95% CI, 43.7%-43.9%), with a hazard ratio for relapse or death of 0.81 (95% CI, 0.68-0.98) (P = .03). Similarly, the 5-year overall survival (OS) was significantly higher in the CT-RT arm (54.0%; 95% CI, 53.9%-54.1%) compared with the RT arm (46.0%; 95% CI, 45.9%-46.1%), with a hazard ratio for death of 0.82 (95% CI, 0.68-0.98; P = .04). After adjusting for prognostic factors, CT-RT continued to be significantly superior to RT for DFS and OS. There was a higher incidence of acute hematological adverse effects in the CT-RT arm. CONCLUSIONS AND RELEVANCE: Chemoradiotherapy using weekly cisplatin results in significantly better DFS and OS compared with RT in women with stage IIIB squamous cell carcinoma of the uterine cervix. This study provides level 1 evidence in the largest clinical trial reported so far in favor of concurrent weekly cisplatin chemotherapy in this setting. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00193791.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32470-x · Cited by 2,412
Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., Fokdal, L. U., Sturdza, A. E., Hoskin, P., Mahantshetty, U., Segedin, B., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30753-1 · Cited by 670
Self-citationAuger electrons for cancer therapy – a review
Ku, A., Facca, V. J., Cai, Z., & Reilly, R. M. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0075-2 · Cited by 643
Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., Acevedo, A., Sukhin, V., Cloven, N., Pereira de Santana Gomes, A. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00317-9 · Cited by 410
Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Chino, J., Annunziata, C. M., Beriwal, S., Bradfield, L., Erickson, B. A., Fields, E. C., Fitch, K., Harkenrider, M. M., Holschneider, C. H., Kamrava, M., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.04.002 · Cited by 313
Metadata
- Authors
- Shrivastava, S., Mahantshetty, U., Engineer, R., Chopra, S., Hawaldar, R., Hande, V., Kerkar, R. A., Maheshwari, A., Shylasree, T. S., Ghosh, J., Bajpai, J., Gurram, L., Gulia, S., Gupta, S., & for the Gynecologic Disease Management Group
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-04-01
- Volume
- 4
- Issue
- 4
- Pages
- 506
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2793545474
- Cited by
- 192
- References
- 0
- FWCI
- 19.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2017.5179
- The paper
- Shrivastava, S., Mahantshetty, U., Engineer, R., Chopra, S., Hawaldar, R., Hande, V., Kerkar, R. A., Maheshwari, A., Shylasree, T. S., Ghosh, J., Bajpai, J., Gurram, L., Gulia, S., Gupta, S., & for the Gynecologic Disease Management Group. (2018). Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2017.5179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.